Abstracts tagged "psoriatic arthritis and treatment"

Abstract Number: 3095 • 2016 ACR/ARHP Annual Meeting
What Should be the Primary Target of ‘Treat to Target’ in Psa?
Laura C. Coates^1,2, Paul Emery³, Philip G. Conaghan¹ and Philip S. Helliwell¹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In 2013, Treat to Target (T2T) in SpA Recommendations by expert consensus stated that the target of treatment should be remission or inactive disease.…
Abstract Number: 679 • 2015 ACR/ARHP Annual Meeting
Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres
Dörte Huscher¹, Katinka Albrecht², Sascha Bischoff², Katja Thiele², Frank Behrens³, Kathrin Fischer⁴, Ulrich von Hinüber⁵, Susanna Späthling-Mestekemper⁶, Siegfried Wassenberg⁷ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁴Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, ⁵Practice-based rheumatologist, Hildesheim, Germany, ⁶Practice-based rheumatologist, München, Germany, ⁷Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden…
Abstract Number: 2855 • 2015 ACR/ARHP Annual Meeting
Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study
Michaela Koehm^1,2, Tanja Rossmanith³, Ulf Henkemeier⁴, Peer Aries⁵, Rieke Alten⁶, Hans-Eckhard Langer⁷, Harald Burkhardt^8,9 and Frank Behrens^1,9, ¹Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ³Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ⁴Centre of Innovative Diagnostics and Therapeutics Rheumatology/Immunology at Goethe-University, Frankfurt, Germany, ⁵Rheumatologie im Struenseehaus, Hamburg, Germany, ⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁷RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁸Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disorder. AntiTNF-therapy is initiated after failure of NSAID and DMARD-treatment. Up to 30-40% of the patients are…
Abstract Number: 2858 • 2015 ACR/ARHP Annual Meeting
A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis
Ignacio-Alfredo Valerio-Morales¹, Maria A. Lopez-Olivo², Xin Pan³ and Maria E. Suarez-Almazor⁴, ¹Rheumatology, National Institute of Rehablitation, Mexico, Mexico, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Inhibition of phosphodiesterase (PDE) family enzymes is now recognized as target to develop new psoriatic arthritis (PsA) drugs. We conducted a systematic review to…
Abstract Number: 651 • 2015 ACR/ARHP Annual Meeting
The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Philip J. Mease¹, Arthur Kavanaugh², Laura C Coates³, Iain McInnes⁴, Maja Hojnik⁵, Ying Zhang⁶, Jaclyn K. Anderson⁶, Alex Dorr⁶ and Dafna Gladman⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of California San Diego, La Jolla, CA, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, North Chicago, IL, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA)1 is a clinically meaningful and comprehensive treatment target for psoriatic arthritis (PsA). The purpose was to determine if baseline (BL)…
Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 1577 • 2014 ACR/ARHP Annual Meeting
Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Philip J. Mease², Laura C. Coates³, Iain B. McInnes⁴, Maja Hojnik⁵, Alex Dorr⁶, Ying Zhang⁶, Benoit Guerette⁶, Alan Friedman⁶ and Dafna D. Gladman⁷, ¹University of California San Diego, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The prediction of treatment outcomes based on early response could be useful in guiding decisions to adjust therapy. The objective was to determine if…
Abstract Number: 952 • 2014 ACR/ARHP Annual Meeting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis
Philip J. Mease¹, A B Gottlieb², A Berman³, E Drescher⁴, J Xing⁵, S Banerjee⁵ and R Wong⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁴Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: New treatment options for psoriatic arthritis (PsA) are needed and interleukin-6 (IL-6), a cytokine with a central role in chronic inflammation, is a potential…
Abstract Number: 1558 • 2013 ACR/ARHP Annual Meeting
Drug Trends In Psoriatic Arthritis
Arane Thavaneswaran¹, Gideon Kalman-Lamb¹, Teneille Loo², Vinod Chandran³ and Dafna D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is now recognized as a potentially severe form of arthritis which requires aggressive medical therapy. The aim of this study was…
Abstract Number: 355 • 2013 ACR/ARHP Annual Meeting
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis
Bernard Combe¹, Urs Kerkmann², Fiona Brock³ and Gaia Gallo², ¹Hôpital Lapeyronie-Service d'Immuno-rhumatologie, Montpellier, France, ²Pfizer Europe, Rome, Italy, ³Quanticate, Hitchin, Hertfordshire, United Kingdom
Background/Purpose: Randomized controlled trials in psoriatic arthrtitis (PsA) have allowed treatment with TNF inhibitors (TNFi) as monotherapy as well as co-medication with methotrexate (MTX), but…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 1374 • 2012 ACR/ARHP Annual Meeting
Value of C-Reactive Protein Level At Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors
Yair Molad¹ and Shachaf Ofer-Shiber², ¹Rheumatology Unit, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petach-Tikva, Israel, ²Internal Medicine H, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
Background/Purpose: To determine the value of acute-phase reactant levels at diagnosis of psoriatic arthritis in predicting the risk of failure of conventional treatment with disease-modifying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].